Select publications

Brufsky A et al. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): Preliminary results of the Z-FAST trial. San Antonio Breast Cancer Symposium 2004;Abstract 1114.

Buzdar AU et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676-85. Abstract

Cobleigh MA et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639-48. Abstract

Come SE, Borges VF. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer 2005;6(Suppl 1):15-22. Abstract

De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;16(Suppl 4):iv7-iv13. Abstract

Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005;[Epub ahead of print]. Abstract

Fisher B et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684-90. Abstract

Gnant M et al. Zoledronic acid effectively counteracts cancer treatment-induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen: Bone density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio Breast Cancer Symposium 2004;Abstract 6.

Gradishar WJ. Clinical value of fulvestrant in breast cancer. Clin Breast Cancer 2005;6(Suppl 1):4. No abstract available

Gradishar WJ, Sahmoud T. Current and future perspectives on fulvestrant. Clin Breast Cancer 2005;6(Suppl 1):23-9. Abstract

Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol 2005;93(2-5):237-47. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2005;6(Suppl 1):9-14. Abstract

Kudachadkar R, O’Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005;55(3):145-63. Abstract

Leonard R et al. Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda). Semin Oncol 2004;31(5 Suppl 10):21-8. Abstract

Marty M et al. Anthracyclines vs taxanes plus trastuzumab in HER2-positive metastatic breast cancer (MBC): A cross trial comparison of pivotal studies. Proc ASCO 2005;Abstract 743.

Marty M et al. Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: Results of a Randomized Phase II Trial by the M77001 Study Group. J Clin Oncol 2005;[Epub ahead of print]. Abstract

Montemurro F et al. Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005;23(12):2866-8. No abstract available

Montemurro F et al. Outcome of patients with HER2+ advanced breast cancer (ABC) progressing during trastuzumab (T)-based treatment. Proc ASCO 2005;Abstract 593.

O’Shaughnessy J et al. ABI-007 (ABRAXANE ), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: A phase III trial. Presentation. San Antonio Breast Cancer Symposium 2003;Abstract 44.

Paley M et al. Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer. Proc ASCO 2005;Abstract 619.

Pippen J et al. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: A prospective combined survival analysis of two multicenter trials. Poster. San Antonio Breast Cancer Symposium 2003;Abstract 426.

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract

Schaller G et al. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer. Proc ASCO 2005;Abstract 717.

Seidman A et al. CALGB 9840: Phase III study of weekly paclitaxel via a 1-hour infusion versus standard 3-hour infusion every third week on the treatment of metastasic breast cancer with trastuzumab for HER2 positive metastatic breast cancer and randomized for trastuzumab in HER2 normal metastatic breast cancer. Proc ASCO 2004;Abstract 512.

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Thürlimann B. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind phase III study. Breast 2005;14(Suppl 1):3;S4.

Tripathy D et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22(6):1063-70. Abstract